



19 April 2021

Incanthera plc

("Incanthera" or the "Company")

Directors dealings

Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology announces the purchase of shares in the Company by Directors of the Board and Senior Management Team (the "Transactions").

The Transactions, recorded on 15 April 2021, on AQSE Growth Market, are as follows:

Employee	Company Position	Transaction Volume	Purchase Price
Tim McCarthy	Chairman	49,382	13.50p
Simon Ward	CEO	51,593	13.50p
Pawel Zolnierzyck	COO	11,307	13.20p
Laura Brogden	CFO	15,057	13.15p
Suzanne Brocks	Head of Communications	50,000	13.00p

Total Shareholdings following the Transactions:

Employee	Company Position	Total Shareholding	% of Share Capital
Tim McCarthy	Chairman	3,931,646	5.31%
Simon Ward	CEO	2,704,199	3.65%
Pawel Zolnierzyck	COO	669,544	0.90%
Laura Brogden	CFO	46,034	0.06%
Suzanne Brocks	Head of Communications	325,594	0.44%

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

For further enquiries:

Incanthera plc
www.incanthera.com

Tim McCarthy, Chairman
tim.mccarthy@incanthera.com

+44 (0) 7831 675747

Simon Ward, Chief Executive Officer

+44 (0) 7747 625506

simon.ward@incanthera.com

Suzanne Brocks, Head of Communications
suzanne.brocks@incanthera.com

+44 (0) 7776 234600

Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/James Lewis/Mark Rogers

+44 (0) 20 7213 0880

Broker:
Stanford Capital Partners Ltd
Patrick Claridge/Tom Price/John Howes/Bob Pountney

+44 (0) 20 3815 8880

Notes to Editors

Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: www.incanthera.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities/ person closely associated with them.

1.	Details of the person discharging managerial responsibilities/person closely associated											
	Name	<table border="1"><tr><td>1. Tim McCarthy</td><td>Chairman</td></tr><tr><td>2. Simon Ward</td><td>CEO</td></tr><tr><td>3. Pawel Zolnierczyk</td><td>PDMR</td></tr><tr><td>4. Laura Brogden</td><td>PDMR</td></tr><tr><td>5. Suzanne Brocks</td><td>PDMR</td></tr></table>	1. Tim McCarthy	Chairman	2. Simon Ward	CEO	3. Pawel Zolnierczyk	PDMR	4. Laura Brogden	PDMR	5. Suzanne Brocks	PDMR
1. Tim McCarthy	Chairman											
2. Simon Ward	CEO											
3. Pawel Zolnierczyk	PDMR											
4. Laura Brogden	PDMR											
5. Suzanne Brocks	PDMR											
2.	Reason for the notification											
a)	Position/status	As above										
b)	Initial notification/Amendment	Initial Notification										

3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor																			
a)	Name	Incanthera plc																		
b)	LEI	2138002HEV4UFBOEXQ97																		
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted																			
a)	Description of the financial instrument	Ordinary Shares of 0.02p																		
b)	Identification code	GB00BGL7YW15																		
c)	Nature of the transactions	Purchase of Ordinary Shares																		
d)	Volumes and Prices	<table border="1"> <thead> <tr> <th></th> <th>Volume</th> <th>Price</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>49,382</td> <td>13.50p</td> </tr> <tr> <td>2.</td> <td>51,593</td> <td>13.50p</td> </tr> <tr> <td>3.</td> <td>11,307</td> <td>13.20p</td> </tr> <tr> <td>4.</td> <td>15,057</td> <td>13.15p</td> </tr> <tr> <td>5.</td> <td>50,000</td> <td>13.00p</td> </tr> </tbody> </table>		Volume	Price	1.	49,382	13.50p	2.	51,593	13.50p	3.	11,307	13.20p	4.	15,057	13.15p	5.	50,000	13.00p
	Volume	Price																		
1.	49,382	13.50p																		
2.	51,593	13.50p																		
3.	11,307	13.20p																		
4.	15,057	13.15p																		
5.	50,000	13.00p																		
e)	Aggregated information - Aggregated volume - Price	<table border="1"> <thead> <tr> <th>Volume</th> <th>Prices</th> </tr> </thead> <tbody> <tr> <td>177,339</td> <td>13.00-13.50p</td> </tr> </tbody> </table>	Volume	Prices	177,339	13.00-13.50p														
Volume	Prices																			
177,339	13.00-13.50p																			
f)	Date of the transactions	15 th April 2021																		
f)	Place of the transactions	AQSE Growth Market, UK																		